We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Response to Eculizumab (PNH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03472885
Recruitment Status : Active, not recruiting
First Posted : March 21, 2018
Results First Posted : June 25, 2021
Last Update Posted : August 17, 2022
Sponsor:
Collaborator:
Achillion, a wholly owned subsidiary of Alexion
Information provided by (Responsible Party):
Alexion Pharmaceuticals

Brief Summary:
To determine the effectiveness of ACH-0144471 (also known as danicopan and ALXN2040) in improving anemia when given with eculizumab for 24 weeks in participants with PNH. Danicopan dose may be increased within each participant, to a maximum of 200 milligrams (mg) three times daily (TID) based on safety and efficacy at protocol-specified time points.

Condition or disease Intervention/treatment Phase
Paroxysmal Nocturnal Hemoglobinuria (PNH) Drug: Danicopan Drug: Eculizumab Phase 2

Detailed Description:

The purpose of this study is to determine the effectiveness of danicopan in improving anemia, as measured by increased blood hemoglobin, when given with eculizumab (a drug commonly used for treatment of PNH) for 24 weeks in participants with PNH.

The 24-week treatment period was followed by a long-term extension phase (ongoing). In the extension phase, participants receive the same danicopan dose plus eculizumab as they were receiving at the end of 24-week treatment phase.

Results are reported for the 24-week treatment period.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: Four groups will be studied and enrolled sequentially.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Open-label Study of ACH-0144471 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have an Inadequate Response to Eculizumab Monotherapy
Actual Study Start Date : May 8, 2018
Actual Primary Completion Date : September 20, 2019
Estimated Study Completion Date : July 31, 2023


Arm Intervention/treatment
Experimental: Group 1: 100 mg Danicopan TID + Eculizumab
Starting dose of 100 mg danicopan TID in combination with eculizumab.
Drug: Danicopan
Participants received a daily oral dose of danicopan TID during the treatment period.

Drug: Eculizumab
Participants received intravenous eculizumab administered at the participant's usual dose and schedule.
Other Name: Soliris

Experimental: Group 2: Initial dose 100 or 150 mg Danicopan TID + Eculizumab
Starting dose of 100 or 150 mg danicopan TID in combination with eculizumab.
Drug: Danicopan
Participants received a daily oral dose of danicopan TID during the treatment period.

Drug: Eculizumab
Participants received intravenous eculizumab administered at the participant's usual dose and schedule.
Other Name: Soliris

Experimental: Group 3: Initial dose of 100, 150, or 200 mg Danicopan TID + Eculizumab
Starting dose of 100, 150, or 200 mg danicopan TID in combination with eculizumab.
Drug: Danicopan
Participants received a daily oral dose of danicopan TID during the treatment period.

Drug: Eculizumab
Participants received intravenous eculizumab administered at the participant's usual dose and schedule.
Other Name: Soliris

Experimental: Group 4: Optimal Dose of Danicopan TID + Eculizumab
Optimal dose (starting dose of either 100, 150, or 200 mg, as determined from Groups 1-3) of danicopan TID in combination with eculizumab.
Drug: Danicopan
Participants received a daily oral dose of danicopan TID during the treatment period.

Drug: Eculizumab
Participants received intravenous eculizumab administered at the participant's usual dose and schedule.
Other Name: Soliris




Primary Outcome Measures :
  1. Change From Baseline In Hemoglobin At Week 24 [ Time Frame: Baseline, Week 24 ]

Secondary Outcome Measures :
  1. Number Of Units Of Red Blood Cells (RBCs) Transfused During 24 Weeks Of Treatment [ Time Frame: From 24 weeks prior to first dose through 24 weeks of treatment ]
  2. Number Of Participants Without RBC Transfusions [ Time Frame: From 24 weeks prior to first dose through 24 weeks of treatment ]
  3. Change From Baseline In Lactate Dehydrogenase At Week 24 [ Time Frame: Baseline, Week 24 ]
  4. Number Of Participants With Serious Adverse Events (SAEs), Grade 3 And Grade 4 Adverse Events (AEs), And Events Leading To Discontinuation Of Study Drug [ Time Frame: Day 1 (after dosing) through 24 weeks ]
    An AE was as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An SAE was an AE that met at least 1 of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization for the AE, persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, congenital anomaly/birth defect (in the child of a participant who was exposed to the study drug), important medical event or reaction. The intensity of an AE was graded according to the Common Terminology Criteria for Adverse Events (CTCAE) Adverse Event Severity Grading Table. Laboratory abnormalities were determined from laboratory measurements analyzed at the central or local laboratories, and were graded using CTCAE. A summary of SAEs and other non-serious AEs regardless of causality is located in the Reported Adverse Events module.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • Diagnosed with PNH
  • Have received at least one red blood cell transfusion within last 12 weeks
  • Anemia with adequate reticulocytosis
  • Must be on a stable regimen of eculizumab
  • Platelet count ≥ 40,000/microliter without the need for platelet transfusions
  • Documentation of vaccination for Neisseria meningitidis, Haemophilus influenza, and Streptococcus pneumoniae or willingness to receive vaccinations based on local guidelines
  • Willingness to receive antibiotic prophylaxis
  • Female participants must use highly effective birth control to prevent pregnancy during the clinical trial and for 30 days after their last dose of study drug
  • Male participants must use a highly effective birth control with a female partner to prevent pregnancy during the clinical trial and for 90 days after the last dose of study drug

Key Exclusion Criteria:

  • Current evidence of bone marrow failure or aplastic anemia requiring treatment
  • History of a major organ transplant or hematopoietic stem cell/marrow transplant
  • Received another investigational agent within 30 days or 5 half-lives of the investigational agent prior to study entry, whichever is greater
  • Documented C5 complement protein mutations
  • Known or suspected complement deficiency
  • Contraindication to any of the required vaccinations
  • Active bacterial infection or clinically significant active viral infection, a body temperature >38°C, or other evidence of infection
  • History of meningococcal infection, or a first-degree relative or household contact with a history of meningococcal infection
  • History of hypersensitivity reactions to commonly used antibacterial agents

Note: Additional inclusion/exclusion criteria may apply, per protocol.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03472885


Locations
Layout table for location information
United States, Maryland
Clinical Study Site
Baltimore, Maryland, United States, 21287
United States, Ohio
Clinical Study Site
Cleveland, Ohio, United States, 44195
Italy
Clinical Study Site
Florence, Italy
Clinical Study Site
Naples, Italy
United Kingdom
Clinical Study Site
London, United Kingdom
Sponsors and Collaborators
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion
  Study Documents (Full-Text)

Documents provided by Alexion Pharmaceuticals:
Study Protocol  [PDF] February 19, 2019
Statistical Analysis Plan  [PDF] March 9, 2020

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Alexion Pharmaceuticals
ClinicalTrials.gov Identifier: NCT03472885    
Other Study ID Numbers: ACH471-101
2016-003526-16 ( EudraCT Number )
U1111-1209-4655 ( Other Identifier: UTN )
First Posted: March 21, 2018    Key Record Dates
Results First Posted: June 25, 2021
Last Update Posted: August 17, 2022
Last Verified: August 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Alexion Pharmaceuticals:
PNH
Paroxysmal Nocturnal Hemoglobinuria
ACH-0144471
Danicopan
Eculizumab
ALXN2040
Additional relevant MeSH terms:
Layout table for MeSH terms
Hemoglobinuria
Hemoglobinuria, Paroxysmal
Proteinuria
Urination Disorders
Urologic Diseases
Urological Manifestations
Anemia, Hemolytic
Anemia
Hematologic Diseases
Myelodysplastic Syndromes
Bone Marrow Diseases
Eculizumab
Complement Inactivating Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs